Back to Top
ICH1128 Compared to BE0036
ICH1128 Compared to BE0036
New independent data from the University of Oxford confirms ICH1128 as a robust, high-performing alternative to BE0036 for in vivo NK cell depletion, delivering near-complete NK cell clearance within days of treatment and consistent, durable depletion across a three-week therapeutic study.
ICH1128 is ichorbio's anti-NK1.1 antibody. BE0036 is the equivalent anti-NK1.1 antibody from Bio X Cell.
 |
Early-Stage Efficacy |
Near-complete NK cell depletion (>98% reduction vs. isotype control) observed just two days after the priming dose. |
 |
Consistent Performance |
Depletion remained tighter and more consistent through Day 21 compared to BE0036, with a slightly lower residual NK cell population. |
 |
Viable Alternative |
A proven, equivalent option to BE0036 for stringent immune cell depletion protocols in therapeutic tumor models. |
ICH1128 vs BE0036: NK Cell Depletion Efficacy
This independent dataset was generated in an L26 NK1.1 depletion study using a subcutaneous MC38 therapeutic tumor model, run by the Valerie Leung Group at the Centre for Immuno-Oncology, Department of Oncology, Medical Sciences Division, University of Oxford.
EARLY-STAGE DEPLETION (DAY 7)
Mice received a 200 µg priming dose by intraperitoneal (i.p.) injection on Day 5. Blood sampled on Day 7 and gated on CD3- cells showed robust NK cell depletion in both antibody groups relative to the isotype control:
● Isotype Control (#ICH2245): 5.93% NK cells
● Bio X Cell (#BE0036): 0.11% NK cells (98.1% depletion vs. isotype)
● ichorbio (#ICH1128): 0.087% NK cells (98.5% depletion vs. isotype)
Figure 1. Representative flow cytometry plots of NK cell frequency (CD3- gate) on Day 7, comparing isotype control, BE0036, and ICH1128.
SUSTAINED DEPLETION (DAY 21)
Following a boost dose on Day 12, prolonged efficacy was assessed on Day 21, again gated on CD3- cells. Both clones maintained excellent depletion through the full three-week study, with ICH1128 trending toward a slightly lower residual NK cell population:
● Isotype Control (#ICH2245): 5.63% NK cells
● Bio X Cell (#BE0036): 0.27% NK cells (95.2% depletion vs. isotype)
● ichorbio (#ICH1128): 0.22% NK cells (96.1% depletion vs. isotype)
Figure 2. Representative flow cytometry plots of NK cell frequency (CD3- gate) on Day 21, comparing isotype control, BE0036, and ICH1128.
Study Overview & Safety Profile
STUDY DESIGN
● Model: Subcutaneous (s.c.) MC38 tumor implantation at Day 0.
● Depletion Regimen: Prime on Day 5, Boost on Day 12.
● Dosing: i.p. 200 µg (in 100 µl PBS).
● Analysis: Flow cytometry with statistical analysis by Kruskal-Wallis test and Dunn's post-hoc test.
Figure 3. Study design schematic: MC38 implantation (Day 0), prime/bleed (Day 5/7), boost/bleed (Day 12/14), and final bleed (Day 21).
GROUP BREAKDOWN
ADVERSE EFFECTS
During routine monitoring, one mouse from Group 3 (ichorbio's anti-NK1.1 antibody, n=4) was found dead spontaneously in its cage on Day 19, prior to the scheduled Day 21 bleed. This animal was therefore excluded from the final Day 21 analysis (n=3 for this timepoint). No other adverse events were observed across the study.
